Oct 17, 2023 / 11:00AM GMT
Ben Shamsian - Lytham Partners - VP
Hello everyone, and thank you all for joining us during your Lytham Partners fall 2023 investor conference. My name is Ben Shamsian, Vice President at Lytham Partners. During this fireside chat, we welcome Delcath Systems, ticker symbol DCTH on the Nasdaq and their CEO, Gerard Michel.
We'll dive into questions in a moment, but one final item I want to remind everyone the drawer is available for one-on-one meetings today. If you have not already signed up, please send me an e-mail at [email protected]. That's [email protected]. Or visit lythampartners.com/virtual and click the one-on-one meeting request button.
A quick introduction on the company. Delcath is an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. The company's primary product the Hepzato kit was recently approved for use in the United States by the FDA, and the company expects initial sales by the end of 2023.
With that said, let's begin. Gerard, good afternoon.
Gerard Michel -
Delcath Systems Inc at Lytham Partners Fall Investor Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers